Anti-Microbialvior BioteQ Co (ROCO:6864) Beginning Cash Position: NT$146.94 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6864 Anti-Microbial Savior BioteQ Co Ltd ROCO:6864
61 GF Score
Price NT$40.60
GF Value NT$25.00
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Anti-Microbialvior BioteQ Co Beginning Cash Position?

Anti-Microbialvior BioteQ Co ROCO:6864 -0.85% 61 Beginning Cash Position is NT$146.94 Mil as of Dec. 2025. GuruFocus rates ROCO:6864 with a GF Score™ of 61/100 and a GF Value™ of NT$25.00 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Anti-Microbialvior BioteQ Co's Beginning Cash Position for the quarter that ended in Dec. 2025 was NT$146.94 Mil.

Anti-Microbialvior BioteQ Co's quarterly Beginning Cash Position increased from Dec. 2024 (NT$123.00 Mil) to Jun. 2025 (NT$194.13 Mil) but then declined from Jun. 2025 (NT$194.13 Mil) to Dec. 2025 (NT$146.94 Mil).

Anti-Microbialvior BioteQ Co's annual Beginning Cash Position declined from Dec. 2023 (NT$131.11 Mil) to Dec. 2024 (NT$78.43 Mil) but then increased from Dec. 2024 (NT$78.43 Mil) to Dec. 2025 (NT$194.13 Mil).

Anti-Microbialvior BioteQ Co Beginning Cash Position Related Terms

Anti-Microbialvior BioteQ Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Anti-Microbialvior BioteQ Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anti-Microbialvior BioteQ Co Beginning Cash Position Chart

Anti-Microbialvior BioteQ Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 92.36 166.58 131.11 78.43 194.13

Anti-Microbialvior BioteQ Co Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.49 78.43 123.00 194.13 146.94
ROCO:6864
61GF Score
Anti-Microbial Savior BioteQ Co Ltd ROCO:6864
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anti-Microbialvior BioteQ Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$146.94 Mil mean?
Anti-Microbialvior BioteQ Co (ROCO:6864) has a Beginning Cash Position of NT$146.94 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Anti-Microbialvior BioteQ Co and its competitors.
Is Anti-Microbialvior BioteQ Co's Beginning Cash Position too high?
Anti-Microbialvior BioteQ Co's current Beginning Cash Position is NT$146.94 Mil. Overall, Anti-Microbialvior BioteQ Co has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Anti-Microbialvior BioteQ Co's Beginning Cash Position compare to VRTX and REGN?
Anti-Microbialvior BioteQ Co's Beginning Cash Position of NT$146.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Anti-Microbialvior BioteQ Co and its competitors. Anti-Microbialvior BioteQ Co's current Beginning Cash Position is NT$146.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anti-Microbialvior BioteQ Co stock overvalued right now?
Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co (ROCO:6864) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.00, compared to a current price of NT$40.60 — trading 62.4% above its estimated fair value. The current Beginning Cash Position is NT$146.94 Mil. Anti-Microbialvior BioteQ Co's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Anti-Microbialvior BioteQ Co (ROCO:6864), the current Beginning Cash Position is NT$146.94 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anti-Microbialvior BioteQ Co (ROCO:6864) Overvalued in 2026?

Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co stock appears to be overvalued. The current stock price of NT$40.60 is trading 62.4% above its estimated GF Value™ of NT$25.00. GuruFocus considers Anti-Microbialvior BioteQ Co to be Significantly Overvalued.

Key valuation signals for ROCO:6864:

  • Beginning Cash Position: NT$146.94 Mil
  • GF Value™: NT$25.00 vs. price of NT$40.60 (62.4% above fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the ROCO:6864 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anti-Microbialvior BioteQ Co Business Description

Address No. 6, Siwei 3rd Road, 7th Floor-2, Lingya District, Kaohsiung, TWN, 741
Anti-Microbial Savior BioteQ Co Ltd is engaged in drug research and development as well as development and technology patenting of medical fungi.
61GF Score

Get the complete analysis for ROCO:6864

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$40.60
Price
NT$25.00
GF Value